| Date Filed | Type | Description |
| 08/11/2020 |
GN
| PFENEX INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout |
| 02/19/2020 |
GN
| INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims |
| 03/05/2019 |
GN
| Detailed Research: Economic Perspectives on Twenty-First Century Fox, Acadia Healthcare, Targa Resources, WellCare Health Plans, Ligand Pharmaceuticals, and Duke Energy — What Drives Growth in Today's Competitive Landscape |
| 03/04/2019 |
GN
| Sermonix to Present Poster at ENDO 2019 on Lasofoxifene's ‘Potent Anti-Tumor Activity' in ESR1 Hormone-Resistant Breast Cancer |
| 02/01/2019 |
GN
| Consolidated Research: 2019 Summary Expectations for Micron Technology, Quidel, Ligand Pharmaceuticals, Altra Industrial Motion, USG, and Equity Lifestyle Properties — Fundamental Analysis, Key Performance Indications |
| 01/29/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm |
| 01/24/2019 |
GN
| Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders |
| 01/17/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm |
| 01/17/2019 |
GN
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ligand Pharmaceuticals Incorporated (LGND) |
| 11/14/2018 |
GN
| Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium |
| 10/22/2018 |
GN
| Analysis: Positioning to Benefit within Ligand Pharmaceuticals, AptarGroup, Unifirst, Universal, AutoZone, and Churchill Downs — Research Highlights Growth, Revenue, and Consolidated Results |
| 10/09/2018 |
GN
| Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board |
| 07/30/2018 |
GN
| Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders |
| 05/08/2018 |
BW
| Ligand Reports First Quarter 2018 Financial Results |
| 04/24/2018 |
BW
| Ligand to Report First Quarter 2018 Results on May 8th |
| 03/06/2018 |
BW
| Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences |
| 02/21/2018 |
BW
| Ligand Reports Fourth Quarter and Full Year 2017 Financial Results |
| 02/05/2018 |
BW
| Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st |
| 11/22/2017 |
GN
| Detailed Research: Economic Perspectives on MACOM Technology Solutions, Whirlpool, Dril-Quip, Ligand Pharmaceuticals, National CineMedia, and F5 Networks — What Drives Growth in Today's Competitive Landscape |
| 11/14/2017 |
BW
| Ligand Provides Highlights from Today's Analyst Day Event |
| 11/09/2017 |
BW
| Ligand Reports Third Quarter 2017 Financial Results |
| 11/06/2017 |
BW
| Reminder: Ligand to Host Analyst Day on November 14th in New York City |
| 10/24/2017 |
BW
| Ligand to Report Third Quarter 2017 Results on November 9th |
| 07/20/2017 |
BW
| Ligand to Report Second Quarter 2017 Results on August 7th |
| 05/22/2017 |
BW
| Ligand to Participate in Two Upcoming Investor Conferences |
| 05/09/2017 |
BW
| Ligand Reports First Quarter 2017 Financial Results |
| 04/13/2017 |
BW
| Ligand to Report First Quarter 2017 Results on May 9th |
| 03/28/2017 |
BW
| Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology |
| 02/28/2017 |
BW
| Ligand Provides Highlights from Today's Analyst Day Event |
| 02/23/2017 |
BW
| Ligand Reports Fourth Quarter and Full Year 2016 Financial Results |
| 02/13/2017 |
BW
| Reminder: Ligand to Host Analyst Day on February 28th in New York City |
| 06/20/2011 |
BW
| Ligand Enters into Captisol® Commercial Supply Agreement with Merck |
| 06/06/2011 |
BW
| Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting |
| 05/10/2011 |
BW
| Ligand Pharmaceuticals Reports First Quarter Results |
|